Introduction: Tricuspid valve (TV) size at birth correlates with intervention strategy in patients with severe pulmonary stenosis (SPS) or pulmonary atresia/intact ventricular septum (PA/IVS). Prenatal features that might predict postnatal TV size have not been well studied. We hypothesized that prenatal echocardiographic measurements predict the postnatal TV Z-score in fetuses with SPS and PA/IVS. Materials and Methods: We identified 16 neonates (gestational age 28 ± 4.8 weeks) with a fetal diagnosis of SPS or PA/IVS from 2001 to 2010. Measurements were performed offline. ROC (receiver operating characteristic) analysis was used to generate AUC (areas under the curve) for each of the variables. Results: AUC was 0.94 for tricuspid to mitral valve (TV/MV) ratio, 0.88 for TV Z-score, and 0.85 for TV inflow duration. A cut-off value of >0.63 for TV/MV yielded a sensitivity of 78%, specificity of 100% for predicting postnatal TV Z-score >-3. Neonates with TV Z-score ≥-3 and all fetuses with antegrade flow across the pulmonary valve or more than moderate tricuspid regurgitation had biventricular circulation in follow-up. Conclusion: Fetal TV/MV >0.63 predicts favorable TV Z-score at birth in patients with SPS and PA/IVS. Antegrade pulmonary valve flow and more than moderate tricuspid regurgitation also conferred a favorable outcome.

Keywords:
Pulmonary atresia with intact ventricular septum, Prenatal predictors, Postnatal outcome, Tricuspid regurgitation
1.
Shinebourne EA, Rigby ML, Carvalho JS: Pulmonary atresia with intact ventricular septum: from fetus to adult: congenital heart disease. Heart 2008;94:1350-1357.
2.
Allan LD, Crawford DC, Tynan MJ: Pulmonary atresia in prenatal life. J Am Coll Cardiol 1986;8:1131-1136.
3.
Maeno YV, Boutin C, Hornberger LK, McCrindle BW, Cavalle-Garrido T, Gladman G, Smallhorn JF: Prenatal diagnosis of right ventricular outflow tract obstruction with intact ventricular septum, and detection of ventriculocoronary connections. Heart 1999;81:661-668.
4.
Hornberger LK, Need L, Benacerraf BR: Development of significant left and right ventricular hypoplasia in the second and third trimester fetus. J Ultrasound Med 1996;15:655-659.
5.
Hornberger LK, Sanders SP, Sahn DJ, Rice MJ, Spevak PJ, Benacerraf BR, McDonald RW, Colan SD: In utero pulmonary artery and aortic growth and potential for progression of pulmonary outflow tract obstruction in tetralogy of Fallot. J Am Coll Cardiol 1995;25:739-745.
6.
Roman KS, Fouron JC, Nii M, Smallhorn JF, Chaturvedi R, Jaeggi ET: Determinants of outcome in fetal pulmonary valve stenosis or atresia with intact ventricular septum. Am J Cardiol 2007;99:699-703.
7.
Gomez-Montes E, Herraiz I, Mendoza A, Albert L, Hernandez-Garcia JM, Galindo A: Pulmonary atresia/critical stenosis with intact ventricular septum: prediction of outcome in the second trimester of pregnancy. Prenat Diagn 2011;31:372-379.
8.
Gardiner HM, Belmar C, Tulzer G, Barlow A, Pasquini L, Carvalho JS, Daubeney PE, Rigby ML, Gordon F, Kulinskaya E, Franklin RC: Morphologic and functional predictors of eventual circulation in the fetus with pulmonary atresia or critical pulmonary stenosis with intact septum. J Am Coll Cardiol 2008;51:1299-1308.
9.
Hanley FL, Sade RM, Blackstone EH, Kirklin JW, Freedom RM, Nanda NC: Outcomes in neonatal pulmonary atresia with intact ventricular septum. A multi-institutional study. J Thorac Cardiovasc Surg 1993;105:406-423.
10.
Peterson RE, Levi DS, Williams RJ, Lai WW, Sklansky MS, Drant S: Echocardiographic predictors of outcome in fetuses with pulmonary atresia with intact ventricular septum. J Am Soc Echocardiogr 2006;19:1393-1400.
11.
Salvin JW, McElhinney DB, Colan SD, Gauvreau K, del Nido PJ, Jenkins KJ, Lock JE, Tworetzky W: Fetal tricuspid valve size and growth as predictors of outcome in pulmonary atresia with intact ventricular septum. Pediatrics 2006;118:e415-e420.
12.
Berning RA, Silverman NH, Villegas M, Sahn DJ, Martin GR, Rice MJ: Reversed shunting across the ductus arteriosus or atrial septum in utero heralds severe congenital heart disease. J Am Coll Cardiol 1996;27:481-486.
13.
Schneider C, McCrindle BW, Carvalho JS, Hornberger LK, McCarthy KP, Daubeney PE: Development of Z-scores for fetal cardiac dimensions from echocardiography. Ultrasound Obstet Gynecol 2005;26:599-605.
14.
Daubeney PE, Sharland GK, Cook AC, Keeton BR, Anderson RH, Webber SA: Pulmonary atresia with intact ventricular septum: impact of fetal echocardiography on incidence at birth and postnatal outcome. UK and Eire Collaborative Study of Pulmonary Atresia with Intact Ventricular Septum. Circulation 1998;98:562-566.
15.
Todros T, Paladini D, Chiappa E, Russo MG, Gaglioti P, Pacileo G, Cau MA, Martinelli P: Pulmonary stenosis and atresia with intact ventricular septum during prenatal life. Ultrasound Obstet Gynecol 2003;21:228-233.
16.
Iacobelli R, Pasquini L, Toscano A, Raimondi F, Michielon G, Tozzi AE, Sanders SP: Role of tricuspid regurgitation in fetal echocardiographic diagnosis of pulmonary atresia with intact ventricular septum. Ultrasound Obstet Gynecol 2008;32:31-35.
17.
Berg C, Kremer C, Geipel A, Kohl T, Germer U, Gembruch U: Ductus venosus blood flow alterations in fetuses with obstructive lesions of the right heart. Ultrasound Obstet Gynecol 2006;28:137-142.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.